Myelomonocytic Leukemia
📧 Sign up to get email alerts when something new happens for Myelomonocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) [Phase 2]
This Phase 2 trial from the University of Manitoba is evaluating antibiotic prophylaxis in patients with myelodysplastic syndrome and acute …
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT [Phase 1]
Stanford is conducting a Phase 1 study evaluating cessation of tacrolimus immunosuppression after allogeneic hematopoietic cell transplantat…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the combination of azacitidine and quizartinib for patients with chronic myelomonocytic leukemia, myel…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia [Phase 2]
A Phase 2 clinical trial evaluating ascorbic acid with chemotherapy for relapsed/refractory lymphoma, clonal cytopenia of undetermined signi…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy
This clinical trial aims to prospectively evaluate plasma cytokine levels, including FLT3 ligand and IL-6, in patients with acute myeloid le…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm [Phase 1, Phase 2]
This update describes a Phase 1/2 clinical trial evaluating a triplet regimen of azacitidine, venetoclax, and gilteritinib in patients with …
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations [Phase 2]
This entry outlines a Phase 2 clinical trial testing olutasidenib in combination with a co-targeted therapy for relapsed or refractory IDH1-…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm [Phase 2]
This clinical trial update reports a Phase 2 study evaluating olutasidenib in combination with hypomethylating agents for IDH1-mutated highe…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [Phase 1]
Phase 1 trial of Vyxeos (CPX-351) is investigating treatment of relapsed or refractory high-risk myelodysplastic syndrome and chronic myelom…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes [Phase 1, Phase 2]
An ongoing Phase I/II clinical trial evaluating Tagraxofusp in combination with Decitabine for patients with chronic myelomonocytic leukemia…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm [Phase 2]
Clinical trial update of a Phase 2 study evaluating venetoclax in combination with ASTX727 (oral decitabine/cedazuridine) for chronic myelom…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia [Phase 2]
Phase II open-label trial evaluating subcutaneous canakinumab (anti-IL-1β) for patients with low- to intermediate-1-risk myelodysplastic syn…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) [Phase 2]
This is a Phase 2 clinical trial update for BLEX 404 Oral Liquid in patients with myelodysplastic syndromes and chronic myelomonocytic leuke…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Cohort of Patients With Chronic Myelomonocytic Leukemia
This document provides an update on a clinical trial cohort for chronic myelomonocytic leukemia, which is currently recruiting participants.
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) [Phase 2, Phase 3]
The AZTOUND study is evaluating ASTX030 (azacitidine and cedazuridine) alone or in combination with venetoclax in myeloid neoplasms includin…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [Phase 1, Phase 2]
Clinical trial update indicates Seclidemstat in combination with azacitidine is being studied for myelodysplastic syndrome or chronic myelom…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Inqovi Maintenance Therapy in Myeloid Neoplasms [Phase 1]
Phase 1 trial update on Inqovi as maintenance therapy for myeloid neoplasms, including myelodysplastic syndromes and chronic myelomonocytic …
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia [EARLY_Phase 1]
This early-phase trial update describes a study evaluating momelotinib in combination with a hypomethylating agent for Chronic Myelomonocyti…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. [Phase 1]
This clinical trial update describes a Phase 1 study of CD4CAR CAR-T therapy as a second-line treatment for chronic myelomonocytic leukemia …
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS [Phase 1]
Phase 1 clinical trial evaluating a combination of epigenetic therapy and sensitising therapy in acute myeloid leukemia, myelodysplastic syn…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation [Phase 2]
This Phase 2 clinical trial protocol investigates a post-transplant cyclophosphamide–based graft-versus-host disease prophylaxis approach in…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias [Phase 1]
Clinical trial update for CBX-250 in relapsed or refractory myeloid leukemias (Phase 1) that is currently recruiting at Crossbow Therapeutic…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia [Phase 1, Phase 2]
Clinical trial update on Axatilimab with or without Azacitidine for advanced myeloproliferative neoplasms, including MDS/MPN overlap and hig…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia [Phase 2]
This clinical trial update describes a Phase 2 study of Ropeginterferon alfa-2b for treating myelodysplastic/myeloproliferative neoplasm ove…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation [Phase 2]
Phase 2 trial update on enasidenib with azacitidine for recurrent or refractory acute myeloid leukemia with IDH2 mutation, currently recruit…